Lilly’s oral GLP-1 shows no liver safety issues in Phase III diabetes trial

US pharma major Eli Lilly (NYSE: LLY) spotlighted new safety and efficacy data for its investigational oral GLP-1 therapy orforglipron at the American Diabetes Association meeting, revealing no liver toxicity and further bolstering its position in the growing diabetes and obesity treatment market.

The once-daily oral drug met its primary target in the 40-week ACHIEVE-1 trial, delivering A1C reductions of up to 1.6% in adults with type 2 diabetes who were not meeting glycemic targets through diet and exercise alone. In a key secondary measure, those on the highest dose lost an average of 16 pounds - nearly 8% of their body weight.